As of November 6, 2026, Nasus Pharma Ltd is a publicly traded company (NYSE: NSRX); its largest reported holder is Balyasny Asset Management L.P., with 9.99% on Schedule 13G/A of August 14, 2026, then Capital Point Ltd. (6.35%). The largest insider holding is Udi Gilboa with 1,924,476 shares (21.3% of shares outstanding), per Form 3 of March 27, 2026 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Nasus Pharma Ltd? See the free Snapshot first.
Free to see. No signup.
Is Nasus Pharma Ltd a real, registered company?
- Nasus Pharma Ltd. files with the SEC under CIK 2029039 (its SEC filings).
- Its shares are listed under the ticker NSRX on NYSE (SEC company record).
- Incorporated in L3; business address in Tel Aviv - Yafo, L3, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Nasus Pharma Ltd in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Balyasny Asset Management L.P. (filed 2026-08-14).
Who are Nasus Pharma Ltd's owners and officers?
Nasus Pharma Ltd: business address in Tel Aviv - Yafo, L3; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-02-25)
- : Executive Officer (Form D, 2026-02-25)
- : Director (Form D, 2026-02-25)
- : Executive Officer, Director (Form D, 2026-02-25)
- : Director (Form D, 2026-02-25)
- : Director (Form D, 2026-02-25)
- : Director (Form D, 2026-02-25)
- : Director (Form D, 2026-02-25)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Balyasny Asset Management L.P. | 9.99% |
| Schedule 13G, 2026-05-15 | Balyasny Asset Management L.P. | 9.99% |
| Schedule 13G, 2026-04-07 | Funicular Funds, LP | 5.2% |
| Schedule 13G, 2025-11-13 | Dr. Ronnie Hershman | 15.3% |
| Schedule 13G, 2025-11-12 | Dr. Dalia Megiddo | 20.9% |
| Schedule 13G, 2025-11-10 | Udi Gilboa | 21.1% |
| Schedule 13G, 2025-08-20 | Capital Point LTD. | 6.35% |
Questions about who owns Nasus Pharma Ltd
Who owns Nasus Pharma Ltd?
On this page, 6 holders' latest ownership filings report 5% or more of Nasus Pharma Ltd: Udi Gilboa (21.1%, Schedule 13G, filed 2025-11-10), Dr. Dalia Megiddo (20.9%, Schedule 13G, filed 2025-11-12), Dr. Ronnie Hershman (15.3%, Schedule 13G, filed 2025-11-13), Balyasny Asset Management L.P. (9.99%, Schedule 13G/A, filed 2026-08-14) and Capital Point LTD. (6.35%, Schedule 13G, filed 2025-08-20); 1 more is listed above.
Who are the largest shareholders of Nasus Pharma Ltd?
By the share each holder's latest filing reports, the largest holders of Nasus Pharma Ltd on this page are Udi Gilboa (21.1%), Dr. Dalia Megiddo (20.9%) and Dr. Ronnie Hershman (15.3%).
When did Udi Gilboa buy into Nasus Pharma Ltd?
The filings give report dates, not purchase dates. The earliest filing from Udi Gilboa on this page is the Schedule 13G, filed 2025-11-10, reporting 21.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Nasus Pharma Ltd?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Nasus Pharma Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nasus Pharma Ltd covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Nasus Pharma Ltd shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Udi Gilboa: 1,924,476 shares (21.3% of shares outstanding), 1,919,281 held directly and 5,195 indirectly (Form 3, 2026-03-27).
- , the chief development officer and a director: 1,894,068 shares (21.0% of shares outstanding), 1,888,873 held directly and 5,195 indirectly (Form 3, 2026-03-27).
- , a director: 1,338,463 shares (14.8% of shares outstanding), held indirectly through By Hershman Holdings, LLC and 1 other (Form 3, 2026-03-27).
- , the chief executive and a director: 163,541 shares (1.8% of shares outstanding) (Form 4, 2026-06-22).
Shares outstanding: 9,015,383 as of 2025-12-31, from the company's latest SEC cover page.
How much has Nasus Pharma Ltd raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-02-25 | $15M | $15M |
Latest IPO step: Nasus Pharma Ltd filed to go public (F-1, 2026-03-02).
IPO filings: F-1, 2026-03-02, 424B4, 2025-08-14, F-1/A, 2025-08-07, F-1/A, 2025-07-28, F-1, 2025-07-09; ticker NSRX on NYSE American.
Keep reading
More on Nasus Pharma Ltd and the records around it.
Nasus Pharma Ltd elsewhere on the record
- 5%+ stake filings Aug 2026
- IPO filing Mar 2026
- Form D filing Feb 2026
Companies that share a holder
- Funicular Funds, LP also filed stake reports on 10 other companies: AmpliTech Group, Inc. (Oct 2026), SYNLOGIC, INC. (Jul 2026), Rein Therapeutics, Inc. (May 2026)
- Balyasny Asset Management L.P. also filed stake reports on 31 other companies: Beyond Air, Inc. (Aug 2026), Camp4 Therapeutics Corp. (Aug 2026), CELLECTAR BIOSCIENCES, INC. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/nasus-pharma